Last updated 23 days ago
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
220 patients around the world
Available in Mexico, Brazil, Spain
Hoffmann-La Roche
9Research sites
220Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Rua Menino Deus, 63 / Bloco A - Sala 303 Centro - Florianópolis - SC
Av. Pontes Vieira, 2571 - Dionísio Torres, Fortaleza - CE, 60135-237
R. Roma, 561 - 4 andar - Santa Lúcia, Belo Horizonte - MG, 30360-680
Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey, Nuevo Leónhttp://www.medicina.uanl.mx/hu/
Dakota 351, Nápoles, Benito Juárez, 03840 Ciudad de México, CDMX, Mexico
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04603807
